Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Keros Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: KROS), announced the appointment of Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. Dr. Seth brings extensive experience in drug development and global operations, having previously served as CEO of Nura Bio and COO of Vir Biotechnology. Her expertise includes leadership roles at Biogen, where she was instrumental in drug commercialization and development. Keros focuses on innovative treatments for hematological, pulmonary, and cardiovascular disorders, with notable candidates such as KER-050 for cytopenias and KER-012 for pulmonary arterial hypertension. The addition of Dr. Seth is seen as a strategic move to enhance the company's capabilities at a crucial time.
Keros Therapeutics (KROS) reported its fourth quarter and full year 2022 financial results, revealing a net loss of $29.7 million for Q4 and $104.7 million for the entire year, significantly up from $6.9 million and $58.7 million in 2021, respectively. The increase is attributed to heightened research and development costs, particularly for the Phase 2 trials of KER-050 targeting myelodysplastic syndromes and myelofibrosis. Keros maintained a strong cash position of $279.0 million as of December 31, 2022, sufficient to fund operations into Q3 2025. The company outlined several key milestones for 2023, including expanded trials for KER-050 and KER-047.
Keros Therapeutics, Inc. (Nasdaq: KROS), a biopharmaceutical company, announced that its President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 11:10 a.m. Eastern time. The event will provide insights into Keros’ innovative treatments for hematological, pulmonary, and cardiovascular disorders. A live audio webcast can be accessed here, with an archived replay available on Keros’ website for up to 90 days post-event.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced participation in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET. President and CEO Jasbir S. Seehra, Ph.D., will represent the company.
A live audio webcast of the event will be available here, with an archived replay accessible on Keros' website for up to 90 days post-event. Keros focuses on novel treatments for hematological, pulmonary, and cardiovascular disorders, including lead candidates KER-050, KER-047, and KER-012.